{"id":963497,"date":"2026-05-15T10:18:20","date_gmt":"2026-05-15T14:18:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-provides-business-update-and-reports-first-quarter-2026-financial-results\/"},"modified":"2026-05-15T10:18:20","modified_gmt":"2026-05-15T14:18:20","slug":"pavmed-provides-business-update-and-reports-first-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-provides-business-update-and-reports-first-quarter-2026-financial-results\/","title":{"rendered":"PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission<\/i>\n <\/p>\n

\n Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones<\/i>\n <\/p>\n

\n PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing<\/i>\n <\/p>\n

\n Conference call and webcast to be held today, May 15, at 8:30 AM EDT<\/i>\n <\/p>\n

\n NEW YORK<\/span>, May 15, 2026<\/span> \/PRNewswire\/ —\u00a0PAVmed Inc.<\/a>\u00a0(NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and reported financial results for the first quarter ended March 31, 2026.<\/p>\n

\n

\n
\n \"PAVmed
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Conference Call and Webcast<\/b>\n <\/p>\n

The\u00a0webcast\u00a0will take place on Friday, May 15, 2026, at 8:30 AM and is accessible in the investor relations section of the Company’s website at pavmed.com<\/a>.\u00a0 Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “PAVmed Business Update” to join.<\/p>\n

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at pavmed.com.<\/p>\n

\n Business Update Highlights<\/b>\n <\/p>\n

“PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy,” said Lishan Aklog, M.D.<\/a>, PAVmed’s Chairman and Chief Executive Officer. “Veris continues to expand its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission, and Lucid continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage. We are also actively advancing multiple technologies within our relaunched medical device portfolio under Joseph Virgilio’s leadership, while increasingly leveraging his experience building and scaling growth-stage businesses.”<\/p>\n

\n Highlights from the first quarter and recent weeks<\/b>:<\/p>\n